Epinephrine Market By Product Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The epinephrine market was valued at $2.6 billion in 2022 and is projected to reach $4.4 billion by 2032, registering a CAGR of 5.6% from 2023 to 2032. Epinephrine, also known as adrenaline, is a hormone and neurotransmitter that plays a vital role in the body's response to stress or danger. It is produced by the adrenal glands, located on top of the kidneys. Epinephrine is released into the bloodstream in response to various stimuli, such as fear, stress, or excitement. Once released, epinephrine triggers a series of physiological responses aimed at preparing the body for action. These responses include increased heart rate, elevated blood pressure, dilation of the airways in the lungs to improve oxygen intake, and redirection of blood flow to the muscles. Epinephrine also enhances alertness and awareness, helping individuals react quickly to challenging situations.

It can be used medicinally, for instance, during ana-phylaxis (severe allergic reactions), cardiac arrest, bronchospasm, or other arrhythmias. Patients take epinephrine by injection inhalers or even nasal sprays; thus, the result helps them get ready for intense physical exertions and/or perceived threats by increase in circulation rates of blood through such mechanisms as air entry and energy availability, among others.

The epinephrine market is driven by the increase in incidence of allergic conditions such as anaphylaxis, asthma, and food allergies. These in turn can provoke strong and potentially lethal reactions that can require epinephrine use as a first line treatment. For instance, according to the American College of Allergy, Asthma, and Immunology (ACAAI), as of 2021, about 20 million people had food allergies in the U.S. Anaphylaxis is a severe and sometimes fatal allergic response that causes breathing problems, throat swelling or a sudden fall in blood pressure if people with devastating food allergies are accidentally exposed to them. In these cases, quick administration of epinephrine is essential to counteract dangerous symptoms, which drives the demand for epinephrine.

In addition, the growth of emergency medical services (EMS) has also been instrumental in propelling the demand for epinephrine within the industry. Paramedics and first responders who attend various life-threatening cases such as cardiac arrest and anaphylaxis among others, are usually given this medicine and thus, it forms a part of their emergency medical kits. The increased availability and accessibility of emergency medical services coupled with rise in demand for emergency care have been key contributors to growth in demand for epinephrine.

Furthermore, the aging population is another factor contributing to the growth of the epinephrine market. As people age, they become more susceptible to allergic reactions and chronic respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD). In these cases, epinephrine may be prescribed as a life-saving medication to manage severe symptoms and prevent complications, which supports the market growth.

However, the regulatory challenges and stringent approval processes for epinephrine products can limit market growth. Regulatory agencies often impose rigorous standards for the manufacturing, labeling, and distribution of epinephrine medications to ensure their safety and efficacy lead to delays in product launches and increased costs for manufacturers, which negatively impacted the market growth. In contrast, technological advancements in drug delivery systems, such as the development of more user-friendly and convenient epinephrine auto-injectors, enhance patient compliance and market penetration. Such innovations in formulation techniques, packaging designs, and device usability are expected to create lucrative opportunities for market growth during the forecast period.

The epinephrine market is segmented on the basis of product type, application, distribution channel, and region. By product type, the market is classified into auto-injector, prefilled syringe, and others. By application, the market is divided into anaphylaxis, cardiac arrest, and others. By distribution channel, it is segregated into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the epinephrine market are Adamis Pharmaceuticals Corporation, AdvaCare Pharma, ALK-Abello A/S, Amneal Pharmaceuticals LLC., Amphastar Pharmaceuticals, Inc., Antares Pharma, kaleo, Inc., Pfizer, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Key players have adopted agreement and product approval as key developmental strategies to improve the product portfolio of the epinephrine market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the epinephrine market analysis from 2022 to 2032 to identify the prevailing epinephrine market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the epinephrine market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global epinephrine market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

Auto-Injector
Prefilled Syringe
Others

By Application

Anaphylaxis
Cardiac Arrest
Others

By Distribution Channel

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Colombia
- Argentina
- Rest Of La
Middle East and Africa
- Gcc
- South Africa
- North Africa
- Rest Of Mea

Key Market Players:

Adamis Pharmaceuticals Corporation
AdvaCare Pharma
ALK
Amneal Pharmaceuticals LLC.
Amphastar Pharmaceuticals, Inc.
Grand Pharma (China) Co., Ltd.
kaleo, Inc.
Pfizer
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Product Code: A65539

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: EPINEPHRINE MARKET, BY PRODUCT TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Auto-Injector
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Prefilled Syringe
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: EPINEPHRINE MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Anaphylaxis
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Cardiac Arrest
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: EPINEPHRINE MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Product Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Product Type
  - 7.2.5.1.2. Market size and forecast, by Application
  - 7.2.5.1.3. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Product Type
  - 7.2.5.2.2. Market size and forecast, by Application
  - 7.2.5.2.3. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Product Type
  - 7.2.5.3.2. Market size and forecast, by Application
  - 7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Product Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Product Type
  - 7.3.5.1.2. Market size and forecast, by Application
  - 7.3.5.1.3. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Product Type
  - 7.3.5.2.2. Market size and forecast, by Application
  - 7.3.5.2.3. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Product Type
  - 7.3.5.3.2. Market size and forecast, by Application
  - 7.3.5.3.3. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Product Type
  - 7.3.5.4.2. Market size and forecast, by Application
  - 7.3.5.4.3. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Product Type
  - 7.3.5.5.2. Market size and forecast, by Application
  - 7.3.5.5.3. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Product Type
  - 7.3.5.6.2. Market size and forecast, by Application
  - 7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Product Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Product Type
  - 7.4.5.1.2. Market size and forecast, by Application
  - 7.4.5.1.3. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Product Type
  - 7.4.5.2.2. Market size and forecast, by Application
  - 7.4.5.2.3. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Product Type
  - 7.4.5.3.2. Market size and forecast, by Application
  - 7.4.5.3.3. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Product Type
  - 7.4.5.4.2. Market size and forecast, by Application
  - 7.4.5.4.3. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Product Type
  - 7.4.5.5.2. Market size and forecast, by Application
  - 7.4.5.5.3. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Product Type
  - 7.4.5.6.2. Market size and forecast, by Application
  - 7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. Latin America
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Product Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Product Type
  - 7.5.5.1.2. Market size and forecast, by Application
  - 7.5.5.1.3. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Colombia
  - 7.5.5.2.1. Market size and forecast, by Product Type
  - 7.5.5.2.2. Market size and forecast, by Application
  - 7.5.5.2.3. Market size and forecast, by Distribution Channel
  - 7.5.5.3. Argentina
  - 7.5.5.3.1. Market size and forecast, by Product Type
  - 7.5.5.3.2. Market size and forecast, by Application
  - 7.5.5.3.3. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest Of La
  - 7.5.5.4.1. Market size and forecast, by Product Type
  - 7.5.5.4.2. Market size and forecast, by Application
  - 7.5.5.4.3. Market size and forecast, by Distribution Channel
7.6. Middle East and Africa
- 7.6.1. Key market trends, growth factors and opportunities
- 7.6.2. Market size and forecast, by Product Type
- 7.6.3. Market size and forecast, by Application
- 7.6.4. Market size and forecast, by Distribution Channel
- 7.6.5. Market size and forecast, by country
  - 7.6.5.1. Gcc
  - 7.6.5.1.1. Market size and forecast, by Product Type
  - 7.6.5.1.2. Market size and forecast, by Application
  - 7.6.5.1.3. Market size and forecast, by Distribution Channel
  - 7.6.5.2. South Africa
  - 7.6.5.2.1. Market size and forecast, by Product Type
  - 7.6.5.2.2. Market size and forecast, by Application
  - 7.6.5.2.3. Market size and forecast, by Distribution Channel
  - 7.6.5.3. North Africa
  - 7.6.5.3.1. Market size and forecast, by Product Type
  - 7.6.5.3.2. Market size and forecast, by Application
  - 7.6.5.3.3. Market size and forecast, by Distribution Channel
  - 7.6.5.4. Rest Of Mea
  - 7.6.5.4.1. Market size and forecast, by Product Type
  - 7.6.5.4.2. Market size and forecast, by Application
  - 7.6.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Adamis Pharmaceuticals Corporation
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. AdvaCare Pharma
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. ALK
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Amneal Pharmaceuticals LLC.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Amphastar Pharmaceuticals, Inc.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Grand Pharma (China) Co., Ltd.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. kaleo, Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Pfizer
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries Ltd.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Viatris Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments